Current Landscape of Non-Small Cell Lung Cancer: Epidemiology, Histological Classification, Targeted Therapies, and Immunotherapy.
Current Landscape of Non-Small Cell Lung Cancer: Epidemiology, Histological Classification, Targeted Therapies, and Immunotherapy.
复制标题
DOI：
10.3390/cancers13184705
复制
发表时间：
2021-09-20
期刊：
影响因子：
5.2
通讯作者：
Dzięgiel P
中科院分区：
文献类型：
--
作者：
Rodak O;Peris-Díaz MD;Olbromski M;Podhorska-Okołów M;Dzięgiel P
非小细胞肺癌研究的丰富性和动态性要求经常总结该领域目前的成就。在我们的综述中，我们旨在更新关于非小细胞肺癌的知识现状，结合其流行病学、分类新颖性、肿瘤分子基础以及两种最有希望的癌症治疗方法：靶向治疗和免疫治疗。非小细胞肺癌(NSCLC)是世界上诊断最多的癌症的一个亚型。它的流行病不仅取决于烟草博览会，还取决于空气质量。虽然全球非小细胞肺癌发病率已经开始下降，但我们可以观察到与患者的教育和经济水平有关的地区差异。随着对非小细胞肺癌生物学认识的加深，新的诊断和治疗策略被开发出来，如重新组织病理学分类或肿瘤基因分型。精密医学专注于识别肺癌细胞中一种名为驱动突变的基因突变，以提供各种功能不正常的蛋白质的特定抑制物。目前，用于非小细胞肺癌靶向治疗的药物迅速增加，可以治疗以下突变蛋白：EGFR家族(ERBB-1、ERBB-2)、ALK、ROS1、MET、RET、NTRK和RAF。然而，最常见的非小细胞肺癌分子亚型之一仍然没有成功的治疗：K-RAS蛋白。在这篇综述中，我们讨论了目前非小细胞肺癌的前景治疗，重点是靶向治疗和免疫治疗，包括一线和二线单一治疗，免疫检查点抑制剂配合化疗，以及已批准的预测性生物标记物。
The abundance and the dynamic of the studies on NSCLC require frequent summaries of the current achievements in the field. In our review, we aimed to update the status of knowledge about NSCLC, combining its epidemiology, classification novelties, tumor molecular basis, and two of the most promising approaches in cancer treatment: targeted therapy and immunotherapy. Non-small cell lung cancer (NSCLC) is a subtype of the most frequently diagnosed cancer in the world. Its epidemiology depends not only on tobacco exposition but also air quality. While the global trends in NSCLC incidence have started to decline, we can observe region-dependent differences related to the education and the economic level of the patients. Due to an increasing understanding of NSCLC biology, new diagnostic and therapeutic strategies have been developed, such as the reorganization of histopathological classification or tumor genotyping. Precision medicine is focused on the recognition of a genetic mutation in lung cancer cells called “driver mutation” to provide a variety of specific inhibitors of improperly functioning proteins. A rapidly growing group of approved drugs for targeted therapy in NSCLC currently allows the following mutated proteins to be treated: EGFR family (ERBB-1, ERBB-2), ALK, ROS1, MET, RET, NTRK, and RAF. Nevertheless, one of the most frequent NSCLC molecular sub-types remains without successful treatment: the K-Ras protein. In this review, we discuss the current NSCLC landscape treatment focusing on targeted therapy and immunotherapy, including first- and second-line monotherapies, immune checkpoint inhibitors with chemotherapy treatment, and approved predictive biomarkers.
登录
查看更多内容
影响因子：
1.9
作者：
Biernacka A;Tsongalis PD;Peterson JD;de Abreu FB;Black CC;Gutmann EJ;Liu X;Tafe LJ;Amos CI;Tsongalis GJ
通讯作者：
Tsongalis GJ
影响因子：
30.8
作者：
Bell, DW;Gore, I;Haber, DA
通讯作者：
Haber, DA
影响因子：
64.8
作者：
Abbosh C;Birkbak NJ;Wilson GA;Jamal-Hanjani M;Constantin T;Salari R;Le Quesne J;Moore DA;Veeriah S;Rosenthal R;Marafioti T;Kirkizlar E;Watkins TBK;McGranahan N;Ward S;Martinson L;Riley J;Fraioli F;Al Bakir M;Grönroos E;Zambrana F;Endozo R;Bi WL;Fennessy FM;Sponer N;Johnson D;Laycock J;Shafi S;Czyzewska-Khan J;Rowan A;Chambers T;Matthews N;Turajlic S;Hiley C;Lee SM;Forster MD;Ahmad T;Falzon M;Borg E;Lawrence D;Hayward M;Kolvekar S;Panagiotopoulos N;Janes SM;Thakrar R;Ahmed A;Blackhall F;Summers Y;Hafez D;Naik A;Ganguly A;Kareht S;Shah R;Joseph L;Marie Quinn A;Crosbie PA;Naidu B;Middleton G;Langman G;Trotter S;Nicolson M;Remmen H;Kerr K;Chetty M;Gomersall L;Fennell DA;Nakas A;Rathinam S;Anand G;Khan S;Russell P;Ezhil V;Ismail B;Irvin-Sellers M;Prakash V;Lester JF;Kornaszewska M;Attanoos R;Adams H;Davies H;Oukrif D;Akarca AU;Hartley JA;Lowe HL;Lock S;Iles N;Bell H;Ngai Y;Elgar G;Szallasi Z;Schwarz RF;Herrero J;Stewart A;Quezada SA;Peggs KS;Van Loo P;Dive C;Lin CJ;Rabinowitz M;Aerts HJWL;Hackshaw A;Shaw JA;Zimmermann BG;TRACERx consortium;PEACE consortium;Swanton C
通讯作者：
Swanton C
影响因子：
51.1
作者：
Altorki, Nasser K.;McGraw, Timothy E.;Formenti, Silvia C.
通讯作者：
Formenti, Silvia C.
影响因子：
10.9
作者：
Brahmer JR;Govindan R;Anders RA;Antonia SJ;Sagorsky S;Davies MJ;Dubinett SM;Ferris A;Gandhi L;Garon EB;Hellmann MD;Hirsch FR;Malik S;Neal JW;Papadimitrakopoulou VA;Rimm DL;Schwartz LH;Sepesi B;Yeap BY;Rizvi NA;Herbst RS
通讯作者：
Herbst RS